Tahata, Yuki
Hikita, Hayato
Mochida, Satoshi
Kawada, Norifumi
Enomoto, Nobuyuki
Ido, Akio
Yoshiji, Hitoshi
Miki, Daiki
Hiasa, Yoichi
Takikawa, Yasuhiro
Sakamori, Ryotaro
Kurosaki, Masayuki
Yatsuhashi, Hiroshi
Tateishi, Ryosuke
Ueno, Yoshiyuki
Itoh, Yoshito
Yamashita, Taro
Kanto, Tatsuya
Suda, Goki
Nakamoto, Yasunari
Kato, Naoya
Asahina, Yasuhiro
Matsuura, Kentaro
Terai, Shuji
Nakao, Kazuhiko
Shimizu, Masahito
Takami, Taro
Akuta, Norio
Yamada, Ryoko
Kodama, Takahiro
Tatsumi, Tomohide
Yamada, Tomomi
Takehara, Tetsuo http://orcid.org/0000-0001-5036-3457
Funding for this research was provided by:
Ministry of Health, Labour and Welfare
Japan Agency for Medical Research and Development (JP20fk0210058)
Gilead Sciences
Article History
Received: 27 May 2020
Accepted: 18 September 2020
First Online: 1 October 2020
Compliance with ethical standards
:
: Satoshi Mochida received grants from Kowa Co, Ltd. CMIC Co., Ltd, AbbVie GK, Janssen Pharmaceutical K. K., EA Pharma Co, Ltd MIC Medical Corp. Sumitomo Dainippon Pharma Co., Ltd, Mochida Pharmaceutical Co., Ltd. Daiichi Sankyo Co., Ltd, Toray Indutries Inc, Chugai Pharmaceutical Co., Ltd, Asuka Pharmaceutical Co., Ltd, Eisai Co., Ltd. and Gilead Sciences, Inc. and is on the speakers’ bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD, Otuka Pharmaceutical Co., Ltd. Sumitomo Dainippon Pharma Co., Ltd. Asuka Pharmaceutical Co., Ltd and AbbVie GK and received patent royalties from SRL Inc. Norifumi Kawada received grants from Gilead Sciences, Inc. and AbbVie GK. and is on the speakers’ bureau for Gilead Sciences, Inc., MSD and AbbVie GK.. Nobuyuki Enomoto received grants from Gilead Sciences, Inc. and is on the speakers’ bureau for Gilead Sciences, Inc.. Akio Ido received grants from AbbVie GK. and is on the speakers’ bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company and AbbVie GK.. Masayuki Kurosaki is on the speakers’ bureau for Gilead Sciences, Inc. Hiroshi Yatsuhashi received grants from AbbVie GK. Yoshiyuki Ueno received grants from EA Pharma Co and AbbVie GK. and is on the speakers’ bureau for AbbVie GK., EA Pharma Co, and Otsuka Pharmaceutical Co. Yoshito Itoh received grants from AbbVie GK, Bristol-Myers Squibb Company, Gilead Sciences, Inc and MSD and is on the speakers’ bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD and AbbVie GK.. Tatsuya Kanto is on the speakers’ bureau for Gilead Sciences, Inc.and MSD. Goki Suda received grants from Gilead Sciences, Inc.. Naoya Kato received grants from Gilead Sciences, Inc., Bristol-Myers Squibb Company and AbbVie GK. and is on the speakers’ bureau for Gilead Sciences, Inc., MSD, Bristol-Myers Squibb Company and AbbVie GK.. Yasuhiro Asahina belongs to a donation-funded department funded by Toray Industries Inc, Gilead Sciences Inc, AbbVie GK, and Fujirebio Inc, Chugai Pharmaceutical Co. Ltd. and MSD. Shuji Terai received grants from Intersterm Routo, Asuka, Tsumura, Chiome Biosciense, Systemx, Touso, Abbvie, Takeda, Eisai, Kyowa, BioMimetics Sympathies and Daiichisannkyo and is on the speakers’ bureau for Gilead Sciences, Inc., Asuka, MSD, Otsuka, Daiichisannkyo and Takeda. Norio Akuta is on the speakers’ bureau for Gilead Sciences, Inc., Bristol-Myers Squibb Company, MSD, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma Co. Ltd and AbbVie GK. Takahiro Kodama received grants from Gilead Sciences, Inc. and AbbVie GK.. Tetsuo Takehara received grants from Gilead Sciences, Inc., MSD, and AbbVie GK. and is on the speakers’ bureau for Gilead Sciences, Inc., MSD, and AbbVie GK.. All other authors declare that they have no conflicts of interest to disclose.
: University Hospital Medical Information Network (UMIN: 000036150).